Table 1.
Author | Year | Method | Manufacturer/platform | Assay | Antigen | Antibody type | COVID‐19 patient samples (n) | Controls (n) |
---|---|---|---|---|---|---|---|---|
A Bown [10] | 2020 | CLIA | Siemens Atellica | Siemens SARS‐CoV‐2 total (COV2T) | S1 | Total antibody | 536 | 976 |
Al‐Jighefee HT [11] | 2021 | ELISA | NA | EDI novel coronavirus COVID‐19 IgG | N | IgG | 291 | 119 |
ELISA | NA | EDI novel coronavirus COVID‐19 IgM | N | IgM | 291 | 119 | ||
Andrey DO [12] | 2021 | ELISA | DYNEX DSX | EDI novel coronavirus COVID‐19 IgG | N | IgG | 172 | 185 |
Bundschuh C [13] | 2020 | ELISA | Serion Diagnostics | EDI novel coronavirus COVID‐19 IgG | N | IgG | 104 | 456 |
ELISA | Serion Diagnostics | EDI novel coronavirus COVID‐19 IgM | N | IgM | 104 | 456 | ||
Chiereghin A [14] | 2020 | CLIA | iFlash 3000 | iFlash‐SARS‐CoV‐2 IgG | N and S | IgG | 207 | 130 |
CLIA | iFlash 3000 | iFlash‐SARS‐CoV‐2 IgM | N and S | IgM | 207 | 130 | ||
Chua KYL [15] | 2020 | CLIA | Vitros 5600 | Ortho‐clinical anti‐SARS‐CoV‐2 IgG | S1 | IgG | 86 | 95 |
CLIA | Beckman Unicel DxI 800 | Access SARS‐CoV‐2 IgG | S1‐RBD | IgG | 86 | 95 | ||
Davidson N [16] | 2020 | ELISA | NA | EDI novel coronavirus COVID‐19 IgG | N | IgG | 71 | 138 |
ELISA | NA | EDI novel coronavirus COVID‐19 IgM | N | IgM | 71 | 138 | ||
Deng Jielun [17] | 2021 | CLIA | iFlash 3000 | iFlash‐SARS‐CoV‐2 IgG | N and S | IgG | 69 | 73 |
CLIA | iFlash 3000 | iFlash‐SARS‐CoV‐2 IgM | N and S | IgM | 69 | 73 | ||
Egger M [18] | 2020 | ELISA | NA | EDI novel coronavirus COVID‐19 IgG | N | IgG | 104 | 200 |
ELISA | NA | EDI novel coronavirus COVID‐19 IgM | N | IgM | 104 | 200 | ||
Florin L [19] | 2021 | CLIA | Siemens Atellica IM1300 | Siemens SARS‐CoV‐2 total (COV2T) | S1‐RBD | Total Ab | 175 | 90 |
Garnett E [20] | 2020 | CLIA | Vitros 5600 | Ortho‐clinical anti‐SARS‐CoV‐2 total | S | Total antibody | 79 | 57 |
Gdoura M [21] | 2022 | CLIA | Beckman Coulter | Access SARS‐CoV‐2 IgG | S1‐RBD | IgG | 72 | 119 |
Han Xiaoyan [22] | 2023 | CLIA | iFlash 3000 | iFlash‐SARS‐CoV‐2 IgG | N and S | IgG | 123 | 41 |
CLIA | iFlash 3000 | iFlash‐SARS‐CoV‐2 IgM | N and S | IgM | 123 | 41 | ||
Harritshøj LH [23] | 2021 | CLIA | Siemens Atellica IM | Siemens SARS‐CoV‐2 total (COV2T) | S1 | Total antibody | 148 | 596 |
CLIA | Siemens Dimension Vista 500 | Siemens SARS‐CoV‐2 total (COV2T) | S1 | Total antibody | 147 | 596 | ||
CLIA | Maglumi 4000+ | MAGLUMI 2019‐nCoV IgG | Unspecified | IgG | 148 | 1173 | ||
CLIA | Maglumi 800 | MAGLUMI 2019‐nCoV IgM | Unspecified | IgM | 150 | 1184 | ||
CLIA | Vitros 3600 | Ortho‐clinical anti‐SARS‐CoV‐2 IgG | S1 | IgG | 150 | 600 | ||
CLIA | Vitros 3600 | Ortho‐clinical anti‐SARS‐CoV‐2 total | S1 | Total antibody | 150 | 605 | ||
ELISA | Tecan Sunrise | Wantai SARS‐CoV‐2 total Ab | S | Total antibody | 150 | 659 | ||
CLIA | iFlash 1800 | iFlash‐SARS‐CoV‐2 IgG | N and S | IgG | 150 | 586 | ||
CLIA | iFlash 1800 | iFlash‐SARS‐CoV‐2 IgM | N and S | IgM | 150 | 585 | ||
Heffernan E [24] | 2021 | ELISA | Dynex DS2 | Wantai SARS‐CoV‐2 total Ab | S | Total antibody | 137 | 100 |
Herroelen PH [25] | 2020 | ELISA | Bio‐Rad Version EIA 0_16 | Wantai SARS‐CoV‐2 total Ab | S1‐RBD | Total antibody | 169 | 57 |
Hörber S [26]a | 2020 | CLIA | Siemens ADVIA Centaur XPT | Siemens SARS‐CoV‐2 total (COV2T) | S1 | Total antibody | 186 | 123 |
Horn MP [27] | 2022 | ELISA | DYNEX DSX | EDI novel coronavirus COVID‐19 IgG | N | IgG | 192 | 3462 |
Igawa G [28] | 2021 | CLIA | Siemens Dimension EXL 200 | Siemens SARS‐CoV‐2 total (COV2T) | S1‐RBD | Total Ab | 236 | 98 |
Ikegami S [29] | 2021 | CLIA | Beckman Coulter | Access SARS‐CoV‐2 IgG | S1‐RBD | IgG | 97 | 100 |
Irsara C [30] | 2021 | CLIA | Siemens ADVIA Centaur XPT | Siemens SARS‐CoV‐2 total (COV2T) | S1 | Total antibody | 195 | 288 |
Kubota K [31] | 2021 | CLIA | Vitros 3600 | Ortho‐clinical anti‐SARS‐CoV‐2 IgG | S | IgG | 66 | 148 |
CLIA | Vitros 3600 | Ortho‐clinical anti‐SARS‐CoV‐2 total | S1 | Total antibody | 66 | 148 | ||
Kundu D [32] | 2022 | CLIA | Siemens ADVIA Centaur XPT | Siemens SARS‐CoV‐2 total (COV2T) | S1 | Total antibody | 153 | 150 |
Lapić I [33] | 2020 | CLIA | Maglumi 800 | MAGLUMI 2019‐nCoV IgG | N and S | IgG | 42 | 48 |
Lester SN [34] | 2024 | CLIA | Vitros ECi/ECiQ/3600 and Vitros 5600/XT 7600 | Ortho‐clinical anti‐SARS‐CoV‐2 total | S1 | Total antibody | 87 | 117 |
Li Ping [35] | 2020 | CLIA | iFlash 3000 | iFlash‐SARS‐CoV‐2 IgG | N and S | IgG | 116 | 134 |
CLIA | iFlash 3000 | iFlash‐SARS‐CoV‐2 IgM | N and S | IgM | 116 | 134 | ||
Mafi S [36] | 2023 | ELISA | NA | Wantai SARS‐CoV‐2 total Ab | S1 | Total antibody | 110 | 120 |
Mairesse A [37] | 2020 | CLIA | iFlash 1800 | iFlash‐SARS‐CoV‐2 IgG | N and S | IgG | 178 | 75 |
CLIA | iFlash 1800 | iFlash‐SARS‐CoV‐2 IgM | N and S | IgM | 178 | 75 | ||
Manthei DM [38] | 2021 | CLIA | Siemens Centaur XP | Siemens SARS‐CoV‐2 total (COV2T) | S1‐RBD | Total Ab | 131 | 188 |
Marlet J [39] | 2020 | ELISA | NA | Wantai SARS‐CoV‐2 total Ab | S | Total Ab | 58 | 89 |
Montesinos I [40] | 2020 | CLIA | Maglumi 800 | MAGLUMI 2019‐nCoV IgG | Unspecified | IgG | 126 | 72 |
CLIA | Maglumi 800 | MAGLUMI 2019‐nCoV IgM | Unspecified | IgM | 126 | 72 | ||
Naaber P [41] | 2020 | CLIA | Maglumi 1000 | MAGLUMI 2019‐nCoV IgG | Unspecified | IgG | 97 | 100 |
ELISA | Dynex Agility | EDI novel coronavirus COVID‐19 IgG | N | IgG | 97 | 100 | ||
Nedelcu I [42] | 2021 | ELISA | Dynex DSX | EDI novel coronavirus COVID‐19 IgG | N | IgG | 528 | 161 |
ELISA | Dynex DSX | EDI novel coronavirus COVID‐19 IgM | N | IgM | 528 | 161 | ||
Nicholson S [43] | 2021 | ELISA | NA | Wantai SARS‐CoV‐2 total Ab | S1 | Total antibody | 96 | 209 |
Nyagwange J [44] | 2022 | ELISA | NA | Wantai SARS‐CoV‐2 total Ab | S1 | Total antibody | 149 | 327 |
Oved K [45] | 2020 | CLIA | Beckman Coulter | Access SARS‐CoV‐2 IgG | S1‐RBD | IgG | 162 | 318 |
2020 | CLIA | Siemens ADVIA Centaur XPT | Siemens SARS‐CoV‐2 total (COV2T) | S1‐RBD | Total Ab | 156 | 432 | |
Padoan A [46] | 2020 | CLIA | Vitros ECi/ECiQ/3600 and Vitros 5600/XT 7600 | Ortho‐clinical anti‐SARS‐CoV‐2 IgG | S | IgG | 130 | 54 |
CLIA | Vitros ECi/ECiQ/3600 and Vitros 5600/XT 7600 | Ortho‐clinical anti‐SARS‐CoV‐2 total | S1 | Total antibody | 130 | 54 | ||
Parai D [47] | 2021 | CLIA | iFlash 1800 | iFlash‐SARS‐CoV‐2 IgG | N and S | IgG | 594 | 100 |
Pérez‐García F [48] | 2021 | CLIA | Siemens Atellica | Siemens SARS‐CoV‐2 total (COV2T) | S1 | Total antibody | 50 | 60 |
Pflüger LS [49] | 2020 | CLIA | Siemens Atellica | Siemens SARS‐CoV‐2 total (COV2T) | S1 | Total Ab | 75 | 320 |
ELISA | Euroimmun Analyzer I‐2 P | Wantai SARS‐CoV‐2 total Ab | S1 | Total Ab | 75 | 320 | ||
Piec I [50] | 2021 | ELISA | Dynex Agility | EDI novel coronavirus COVID‐19 IgG | N | IgG | 43 | 152 |
Riester E [51] | 2021 | CLIA | iFlash 1800 | iFlash‐SARS‐CoV‐2 IgG | N and S | IgG | 104 | 928 |
CLIA | iFlash 1800 | iFlash‐SARS‐CoV‐2 IgM | N and S | IgM | 104 | 928 | ||
Rikhtegaran Tehrani Z [52] | 2020 | ELISA | NA | EDI novel coronavirus COVID‐19 IgG | N | IgG | 97 | 288 |
ELISA | NA | EDI novel coronavirus COVID‐19 IgM | N | IgM | 95 | 299 | ||
Sekirov I [53] | 2021 | CLIA | Vitros XT 7600 | Ortho‐clinical anti‐SARS‐CoV‐2 IgG | S | IgG | 42 | 65 |
CLIA | Vitros XT 7600 | Ortho‐clinical anti‐SARS‐CoV‐2 total | S1 | Total antibody | 42 | 65 | ||
CLIA | Siemens ADVIA Centaur XPT | Siemens SARS‐CoV‐2 total (COV2T) | S1 | Total antibody | 42 | 65 | ||
Şener B [54] | 2022 | CMIA | Beckman Coulter | Access SARS‐CoV‐2 IgG | S1‐RBD | IgG | 125 | 50 |
CMIA | Siemens Atellica | Siemens SARS‐CoV‐2 total (COV2T) | S1‐RBD | Total Ab | 131 | 50 | ||
Serre‐Miranda C [55] | 2021 | CLIA | NA | MAGLUMI 2019‐nCoV IgG | N and S | IgG | 117 | 35 |
CLIA | NA | MAGLUMI 2019‐nCoV IgM | N and S | IgM | 117 | 35 | ||
Soleimani R [56] | 2021 | CLIA | Maglumi 800 | MAGLUMI 2019‐nCoV IgG | N and S | IgG | 176 | 100 |
2021 | CLIA | Maglumi 800 | MAGLUMI 2019‐nCoV IgM | N and S | IgM | 176 | 100 | |
Syre H [57] | 2022 | ELISA | DYNEX DS2 system | Wantai SARS‐CoV‐2 total Ab | S | Total antibody | 211 | 320 |
Tan SS [58] | 2020 | CLIA | Beckman Unicel DxI 800 | Access SARS‐CoV‐2 IgG | S1‐RBD | IgG | 173 | 163 |
CLIA | Siemens ADVIA Centaur XPT | Siemens SARS‐CoV‐2 total (COV2T) | S1 | Total antibody | 173 | 163 | ||
CLIA | Vitros 3600 | Ortho‐clinical anti‐SARS‐CoV‐2 total | S1 | Total antibody | 173 | 163 | ||
Theel ES [59] | 2020 | ELISA | Dynex Agility | EDI novel coronavirus COVID‐19 IgG | N | IgG | 61 | 149 |
CLIA | Vitros 3600 | Ortho‐clinical anti‐SARS‐CoV‐2 IgG | S | IgG | 61 | 149 | ||
Tolan NV [60] | 2023 | ELISA | NA | EDI novel coronavirus COVID‐19 IgG | N | IgG | 105 | 55 |
ELISA | NA | EDI novel coronavirus COVID‐19 IgM | N | IgM | 103 | 57 | ||
Van Elslande J [61] | 2020 | CLIA | Maglumi 800 | MAGLUMI 2019‐nCoV IgG | Unspecified | IgG | 223 | 113 |
Velay A [62] | 2020 | ELISA | NA | EDI novel coronavirus COVID‐19 IgG | N | IgG | 198 | 100 |
ELISA | NA | EDI novel coronavirus COVID‐19 IgM | N | IgM | 198 | 100 | ||
Ward MD [63] | 2021 | CLIA | Siemens Atellica | Siemens SARS‐CoV‐2 total (COV2T) | S1 | Total antibody | 112 | 2030 |
CLIA | Siemens EXL | Siemens SARS‐CoV‐2 total (COV2T) | S1 | Total antibody | 112 | 2030 | ||
Wu Lianpeng [64] | 2021 | CLIA | iFlash 3000 | iFlash‐SARS‐CoV‐2 IgG | N and S | IgG | 179 | 50 |
CLIA | iFlash 3000 | iFlash‐SARS‐CoV‐2 IgM | N and S | IgM | 179 | 50 | ||
Yassine HM [65] | 2021 | ELISA | Epoch 2 | EDI novel coronavirus COVID‐19 IgG | N | IgG | 101 | 70 |
Zilla M [66] | 2021 | CLIA | Beckman Coulter | Access SARS‐CoV‐2 IgG | S1‐RBD | IgG | 154 | 184 |
CLIA | Siemens Centaur XP | Siemens SARS‐CoV‐2 total (COV2T) | S1 | Total antibody | 154 | 184 | ||
CLIA | Siemens Vista 1500 | Siemens SARS‐CoV‐2 total (COV2T) | S1 | Total antibody | 154 | 184 |
If borderline results were considered positive.
Abbreviations: CLIA, chemiluminescent immunoassay; ELISA, enzyme immunoassay; N, nucleocapsid antigen; NA, not specified; RBD, receptor‐binding domain; S1, S1 domain of viral spike protein; S1/S2, recombinant S1 and S2 antigens.